The COVID-19 pandemic continues to evolve with
the emergence of new SARS-CoV-2 variants. The variants of concern have the
potential to impact the transmissibility, virulence, and clinical presentation
of the disease, affecting the epidemiology, public health measures, and
diagnostic and therapeutic options. Mutations in the spike protein of the virus
have increased its ability to infect humans and evade neutralization by natural
or immunisation-induced antibodies. The highly mutated Omicron variant of SARS-CoV-2
has multiple sublineages with varying transmissibility and immune evasion
potential. Pre-exposure prophylaxis plays a crucial role in protecting the
immunocompromised populations against severe disease; however, the rapidly
changing landscape of the variants poses a major challenge to the current and
future effectiveness of pre-exposure prophylactic monoclonal antibodies.